12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MM-111: Phase I data

Data from 29 evaluable patients in an open-label, dose-escalation, U.S. Phase I trial showed that once-weekly MM-111 in combination with chemotherapy led to a clinical benefit rate (CBR) of 52%. Specifically, MM-111 plus cisplatin, capecitabine and trastuzumab produced 11 complete responses (CR), 2 partial responses (PR) and 9 cases of stable disease (SD). MM-111 plus lapatinib and trastuzumab produced 2 PRs. MM-111 plus paclitaxel and trastuzumab produced 4...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >